269 related articles for article (PubMed ID: 19878488)
1. Development of a unit risk factor for 1,3-butadiene based on an updated carcinogenic toxicity assessment.
Grant RL; Haney J; Curry AL; Honeycutt M
Risk Anal; 2009 Dec; 29(12):1726-42. PubMed ID: 19878488
[TBL] [Abstract][Full Text] [Related]
2. A chronic reference value for 1,3-butadiene based on an updated noncancer toxicity assessment.
Grant RL; Haney J; Curry AL; Honeycutt M
J Toxicol Environ Health B Crit Rev; 2010 Aug; 13(6):460-75. PubMed ID: 20711928
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk assessment for 1,3-butadiene: dose-response modeling from an epidemiological perspective.
Sielken RL; Valdez-Flores C; Gargas ML; Kirman CR; Teta MJ; Delzell E
Chem Biol Interact; 2007 Mar; 166(1-3):140-9. PubMed ID: 16876150
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
5. Dose-response implications of the University of Alabama study of lymphohematopoietic cancer among workers exposed to 1,3-butadiene and styrene in the synthetic rubber industry.
Sielken RL; Valdez-Flores C
Chem Biol Interact; 2001 Jun; 135-136():637-51. PubMed ID: 11397418
[TBL] [Abstract][Full Text] [Related]
6. Case-cohort study of styrene exposure and ischemic heart disease.
Matanoski GM; Tao X
Res Rep Health Eff Inst; 2002 May; (108):1-29; discussion 31-7. PubMed ID: 12214600
[TBL] [Abstract][Full Text] [Related]
7. An updated inhalation unit risk factor for arsenic and inorganic arsenic compounds based on a combined analysis of epidemiology studies.
Erraguntla NK; Sielken RL; Valdez-Flores C; Grant RL
Regul Toxicol Pharmacol; 2012 Nov; 64(2):329-41. PubMed ID: 22813725
[TBL] [Abstract][Full Text] [Related]
8. Spatial and temporal trend evaluation of ambient concentrations of 1,3-butadiene and chloroprene in Texas.
Grant RL; Leopold V; McCant D; Honeycutt M
Chem Biol Interact; 2007 Mar; 166(1-3):44-51. PubMed ID: 17011534
[TBL] [Abstract][Full Text] [Related]
9. Butadiene cancer exposure-response modeling: based on workers in the styrene-butadiene-rubber industry: total leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia.
Sielken RL; Valdez-Flores C
Regul Toxicol Pharmacol; 2011 Aug; 60(3):332-41. PubMed ID: 21600953
[TBL] [Abstract][Full Text] [Related]
10. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
[TBL] [Abstract][Full Text] [Related]
11. [A simple method for risk assessment and its application to 1,3-butadiene].
Zocchetti C; Pesatori AC; Bertazzi PA
Med Lav; 2004; 95(5):392-409. PubMed ID: 15595202
[TBL] [Abstract][Full Text] [Related]
12. Quantitative risk assessment of exposures to butadiene in EU occupational settings based on the University of Alabama at Birmingham epidemiological study.
Sielken RL; Valdez-Flores C
Regul Toxicol Pharmacol; 2013 Mar; 65(2):214-25. PubMed ID: 23261476
[TBL] [Abstract][Full Text] [Related]
13. Estimating ambient concentration and cancer risk for 1,3-butadiene in Japan.
Mita K; Higashino H; Yoshikado H; Nakanishi J
Environ Sci; 2006; 13(1):1-13. PubMed ID: 16685248
[TBL] [Abstract][Full Text] [Related]
14. 1,3-Butadiene and leukemia among synthetic rubber industry workers: exposure-response relationships.
Cheng H; Sathiakumar N; Graff J; Matthews R; Delzell E
Chem Biol Interact; 2007 Mar; 166(1-3):15-24. PubMed ID: 17123495
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
16. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
Gaylor DW; Swirsky Gold L
Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm.
Sielken RL; Valdez-Flores C
Chem Biol Interact; 2015 Nov; 241():50-8. PubMed ID: 26070419
[TBL] [Abstract][Full Text] [Related]
18. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
[TBL] [Abstract][Full Text] [Related]
19. A simple method for quantitative risk assessment of non-threshold carcinogens based on the dose descriptor T25.
Sanner T; Dybing E; Willems MI; Kroese ED
Pharmacol Toxicol; 2001 Jun; 88(6):331-41. PubMed ID: 11453374
[TBL] [Abstract][Full Text] [Related]
20. Development of a unit risk factor for nickel and inorganic nickel compounds based on an updated carcinogenic toxicity assessment.
Haney JT; McCant DD; Sielken RL; Valdez-Flores C; Grant RL
Regul Toxicol Pharmacol; 2012 Feb; 62(1):191-201. PubMed ID: 22019551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
